Phase II APEC trial: The impact of primary tumor side on outcomes of first‐line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild‐type metastatic colorectal cancer

AIM: The open‐label, nonrandomized, phase II APEC study enrolled 167 patients with RAS wild‐type (wt) metastatic colorectal cancer (mCRC) to investigate the safety and efficacy of first‐line, every‐2‐weeks cetuximab plus investigator's choice of FOLFIRI or FOLFOX in this patient population. MET...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Asia Pac J Clin Oncol
Päätekijät: Price, Timothy, Shen, Lin, Ma, Brigette, Esser, Regina, Chen, Wenfeng, Gibbs, Peter, Lim, Robert, Cheng, Ann‐Lii
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2019
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6852115/
https://ncbi.nlm.nih.gov/pubmed/31090260
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajco.13154
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia